Dapansutrile

Research use only, not for human use.

Dapansutrile is a potent, selective and orally active NLRP3 inflammasome inhibitor, with Anti-inflammatory and analgesic activity.

Dapansutrile is a potent, selective and orally active NLRP3 inflammasome inhibitor, with Anti-inflammatory and analgesic activity.Dapansutrile is a newly developed drug that is safe in humans and inhibits specifically the NLRP3 inflammasome.

——

Animal Model:EAE-induced female adult C57BL/6 (8–10 weeks old) Dosage:3.75 g/kg Administration:Oral administration; daily, for 22 daysResult:Ameliorated the neurological deficits of EAE disease.Reduced the levels of IL-1β, L-18 , TNFα, CXCL-1 and IL-6. Showed ~2-fold reduction in the infiltration of T cells (CD45+, CD3+). Reduced the accumulation macrophages (CD45high, CD11b+, F4/80+), microglia (CD45low, CD11b+), and other cells (CD45+, CD11b-, CD3-, CD24+).Animal Model:Male ICR (CD1) mice (8-12 weeks old)Dosage:6, 60, and 600 mg/kg Administration:Intraperitoneal injection; onceResult:Reduced infarct size in a dose-dependent manner.Animal Model:Mice subjected to acute myocardial infarction (AMI)Dosage:6, 60, and 600 mg/kg Administration:Intraperitoneal injection; once, for 24 hours and 7 days Result:Preserved left ventricular (LV) systolic function at 24 hours.Increased in cardiac function at 7 days of reperfusion when compared with the control mice.

——

NF-κB

NOD

NLRP3

Inflammation

Schnitzler Syndrome

54863-37-5

133.17

C4H7NO2S

>98% (HPLC)

DMSO:120mg/ml (901.1 Mm)

CS(=O)(=O)CCC#N

——

(-20℃)

With Ice Pack

≥ 2 years